Immunic is trading at $13.51, down -5.13%, with the move appearing driven by stock-specific trading or profit-taking.
- No new negative company-specific announcement was identified for September 3, 2026.
- Broader markets and biotechnology stocks are rising, so sector or global strength does not explain the decline.
- The September 9 virtual multiple-sclerosis R&D Day remains the key near-term catalyst, ahead of expected year-end Phase 3 ENSURE data.